Datasets:

xpertsystems
/

hc-res-007-sample

patient_id string	ild_subtype string	age_at_diagnosis float64	sex string	race_ethnicity string	smoking_status string	pack_years float64	occupational_exposure string	geographic_region string	bmi_at_diagnosis float64	height_cm float64	diagnosis_year int64	follow_up_months_available int64	icd11_code string	hrct_pattern string	fibrosis_extent_pct float64	honeycombing_flag int64	honeycombing_extent_pct float64	ground_glass_opacity_pct float64	traction_bronchiectasis_score float64	subpleural_distribution string	reticulation_extent_pct float64	air_trapping_flag int64	mosaic_attenuation_flag int64	hrct_progression_score_annual_pct float64	imaging_ai_fibrosis_score float64	imaging_platform string	slice_thickness_mm float64	fvc_pct_predicted_baseline float64	fvc_absolute_liters_baseline float64	fvc_decline_ml_per_year float64	dlco_pct_predicted_baseline float64	dlco_decline_pct_per_year float64	tlc_pct_predicted float64	rv_tlc_ratio float64	fev1_fvc_ratio float64	six_min_walk_distance_m int64	six_min_walk_spo2_nadir_pct float64	spo2_at_rest_pct float64	supplemental_oxygen_flag int64	supplemental_oxygen_lpm float64	fvc_response_category string	gap_index int64	composite_physiologic_score float64	loinc_fvc_pct string	loinc_dlco_pct string	treatment_arm string	pirfenidone_dose_mg_day int64	nintedanib_dose_mg_day int64	treatment_start_months_from_dx float64	antifibrotic_adherence_pct float64	dose_reduction_flag int64	treatment_discontinuation_flag int64	discontinuation_reason string	time_to_discontinuation_months float64	fvc_treatment_effect_ml_year float64	corticosteroid_flag int64	corticosteroid_dose_mg_day int64	immunosuppressant string	trial_drug_name string	trial_phase string	kl6_serum_u_ml int64	sp_d_serum_ng_ml float64	ca19_9_u_ml float64	mmp7_serum_ng_ml float64	cxcl13_pg_ml float64	telomere_length_kb float64	short_telomere_flag int64	lysophosphatidic_acid_um float64	ccl18_pg_ml float64	tnf_alpha_pg_ml float64	tgf_beta1_pg_ml float64	periostin_ng_ml float64	biomarker_trend_6m string	antigen_specific_igg_hp int64	ana_titer string	rheumatoid_factor_iu_ml float64	anti_ccp_flag int64	antigen_exposure_score float64	loinc_kl6 string	muc5b_rs35705950 string	tert_mutation_flag int64	terc_mutation_flag int64	sftpc_mutation_flag int64	abca3_mutation_flag int64	familial_ipf_flag int64	genetic_risk_score float64	wgs_available_flag int64	telomere_syndrome_flag int64	ae_ipf_flag int64	ae_count_total int64	ae_trigger string	ae_hospitalization_flag int64	ae_icu_admission_flag int64	ae_90day_mortality_probability float64	ae_steroid_response string	ae_methylprednisolone_dose_mg int64	ae_time_to_first_months float64	post_ae_fvc_decline_ml float64	transplant_listed_flag int64	lung_allocation_score_baseline float64	lung_allocation_score_12m float64	waitlist_mortality_12m_flag int64	transplant_performed_flag int64	bilateral_transplant_flag int64	transplant_timing_months float64	clad_flag int64	survival_post_transplant_years float64	transplant_contraindication_flag int64	primary_annual_outcome string	all_cause_mortality_5yr_flag int64	respiratory_death_flag int64	overall_survival_months float64	hospitalization_any_5yr_flag int64	hospitalization_respiratory_5yr_flag int64	hospitalization_days_total int64	oxygen_requirement_progression string	dyspnea_mrc_score int64	st_george_qol_score float64	king_ild_score float64	ucsd_sobq_score float64	cci_comorbidity_index int64	pulmonary_hypertension_flag int64	emphysema_cpfe_flag int64	gerd_flag int64	obstructive_sleep_apnea_flag int64	cvd_comorbidity_flag int64
HC007-000001	CTD-ILD	72.2	Female	Black_Non-Hispanic	Former_Smoker	12.2	null	North_America	31.8	161.5	2,010	15	CB03.1Z	Indeterminate	17	0	0	7.9	0.7	Bilateral_Basal	23.5	0	1	5.55	15.1	GE	0.51	66.1	1.87	20	53.6	-5.17	53.6	0.401	0.822	366	88.9	92	0	0	Slow_Decliner	6	0	19876-2	19911-7	Untreated	0	0	3.4	0.739	0	0	null	null	0	1	58	null	null	null	521	32.1	18.8	8.72	712.2	6.07	0	2.035	174	3.44	15.16	11.06	Increasing	0	1:40-1:80	1.1	0	1.1	15088-0	TT_Wildtype	0	0	0	0	1	2.5	0	0	0	0	null	0	0	0	null	0	null	null	0	55.3	79.2	0	0	0	null	0	null	1	Progression	0	0	120	1	1	14	Exertional_to_Continuous	1	70.1	70.8	29.4	4	1	0	0	1	0
HC007-000002	IPF	67.9	Male	White_Non-Hispanic	Former_Smoker	34.5	Bird_Antigen	Other	20.2	180.6	2,012	24	CB03.10	UIP	36.9	0	0	7	2.2	Peripheral	14.1	0	0	4.17	35.2	Siemens	0.69	56.5	2.09	-213.1	69.2	-8.25	58.4	0.448	0.826	426	85.7	91.8	1	2.2	Stable	3	0	19876-2	19911-7	Untreated	0	0	2.9	0.777	0	0	null	null	0	0	0	Mycophenolate	null	null	1,172	51.5	10.8	9.68	258.4	3.96	1	2.183	612.3	20.05	44.18	19.09	Increasing	0	Negative	12.8	0	3.6	15088-0	TT_Wildtype	1	0	0	0	0	34.2	0	0	0	0	null	0	0	0	null	0	null	null	0	51	70	0	0	0	null	0	null	1	Death	0	0	42.4	0	1	0	Exertional_to_Continuous	4	77.7	77.4	27.3	4	0	1	1	1	1
HC007-000003	NSIP	70	Female	White_Non-Hispanic	Former_Smoker	40.5	Mold	Europe	22.5	165.4	2,012	49	CB03.11	Indeterminate	10.9	0	0	43	1.6	Bilateral_Basal	30.6	0	0	4.54	12.6	GE	1.19	102	2.5	-85.5	67.9	-0.89	55	0.322	0.904	394	87	93.7	0	0	Fast_Decliner	4	0	19876-2	19911-7	Untreated	0	0	2.5	0.893	0	0	null	null	0	0	0	null	null	null	1,103	81.5	58.7	6.99	618.7	6.11	0	2.226	536.5	8.09	11.75	16.41	Stable	0	Negative	8.4	0	2.6	15088-0	TT_Wildtype	0	1	0	0	0	21.3	0	0	0	0	null	0	0	0	null	0	null	null	0	32.7	48.7	0	0	0	null	0	null	1	AE	0	0	20.1	1	1	49	Stable	3	37	24.8	53.6	3	0	0	0	1	0
HC007-000004	CTD-ILD	54.3	Male	Other	Former_Smoker	21.7	Wood_Dust	North_America	29.2	178	2,010	60	CB03.1Z	Probable_UIP	9.1	0	0	3.5	0.6	Bilateral_Basal	49.5	0	1	3.15	8.3	GE	0.53	39.6	1.97	-128.1	38.1	-3.49	56.8	0.331	0.78	545	80.8	96.4	0	0	Slow_Decliner	4	22.2	19876-2	19911-7	Untreated	0	0	11.9	0.838	0	0	null	null	0	0	0	null	null	null	643	65	30.6	9.66	467	5.47	0	4.679	597.7	7.45	22.93	13.66	Increasing	0	Negative	10.5	0	2	15088-0	TG_Het	0	0	0	0	0	33.8	0	0	1	2	Drug_Reaction	1	0	0.609	Partial	500	25.8	-174.2	0	15	26.3	0	0	0	null	0	null	0	Death	1	1	92.8	1	0	18	Exertional_to_Continuous	1	53.2	95.7	18.4	5	0	0	0	0	1
HC007-000005	IPF	65.3	Male	White_Non-Hispanic	Former_Smoker	35.5	Wood_Dust	North_America	16.3	170.8	2,011	37	CB03.10	UIP	28.8	0	0	5.2	1.8	Bilateral_Basal	47.1	0	0	4.93	33.5	GE	1.1	93.1	3.35	-97	32.4	-1.29	91.8	0.42	0.774	243	83.6	95.5	1	2	Slow_Decliner	4	1.7	19876-2	19911-7	Pirfenidone	1,602	0	3.3	0.711	0	0	null	null	123.9	0	0	Azathioprine	null	null	714	32	14.4	18.46	417.4	5.73	0	2.403	489.4	10.96	8.33	40.36	Decreasing	0	Negative	26.3	0	2	15088-0	TG_Het	0	1	0	0	0	51.3	0	0	0	0	null	0	0	0	null	0	null	null	0	44.5	58.1	0	0	0	null	0	null	1	Death	1	0	7.1	1	1	53	Stable	2	42.9	41.5	34.3	4	0	0	1	0	1
HC007-000006	SR-ILD	53.6	Male	White_Non-Hispanic	Former_Smoker	6.2	null	North_America	27.3	172.9	2,018	39	CB03.13	Alternative_Dx	11.9	0	0	7.7	3.1	Bilateral_Basal	44.5	0	0	1.37	8.6	Philips	0.67	67.2	3.1	-67.2	29.5	-2.26	73.2	0.465	0.791	424	86.7	91.7	0	0	Slow_Decliner	3	0	19876-2	19911-7	Untreated	0	0	4.5	0.809	0	0	null	null	0	0	0	null	null	null	2,775	105.2	10.9	16.79	141.2	5.81	0	12.733	574.3	5.11	11.21	16.73	Stable	0	Negative	4.3	0	8.6	15088-0	TG_Het	0	0	0	0	0	28.7	0	0	0	0	null	0	0	0	null	0	null	null	0	29.5	31.6	0	0	0	null	0	null	0	Stable	1	1	41.1	0	0	0	None_to_Exertional	1	37.4	13.2	62.9	2	0	0	0	0	0
HC007-000007	CTD-ILD	60.2	Male	White_Non-Hispanic	Never	0	Asbestos	North_America	22.2	168.9	2,019	50	CB03.1Z	Alternative_Dx	25.1	0	0	13.4	1.6	Bilateral_Basal	22.7	0	0	1.66	26.8	GE	0.66	72.7	3.71	-80	90	-1.29	96.5	0.344	0.821	240	85.7	96	0	0	Stable	2	0	19876-2	19911-7	Untreated	0	0	0.5	0.76	0	0	null	null	0	1	58	null	null	null	498	127.3	6.9	14.57	353.3	4.15	1	5.368	333.3	12.09	14.53	12.37	Stable	1	1:40-1:80	5.8	0	2.9	15088-0	TT_Wildtype	0	0	0	0	0	20	0	1	0	0	null	0	0	0	null	0	null	null	0	48.1	51.6	0	0	0	null	0	null	1	AE	0	0	26.3	0	0	0	None_to_Exertional	1	35.8	25	48.5	3	0	0	0	1	0
HC007-000008	CTD-ILD	44.8	Male	White_Non-Hispanic	Former_Smoker	22.7	null	Europe	28	173.7	2,011	19	CB03.1Z	Probable_UIP	32.3	1	19.1	4.9	0.7	Bilateral_Basal	23.3	1	0	4.06	30.8	GE	1.57	67.9	2.62	-191.6	44.2	-4.63	71.2	0.306	0.723	424	87.5	91.1	0	0	Slow_Decliner	2	0.3	19876-2	19911-7	Untreated	0	0	1.1	0.887	0	0	null	null	0	0	0	Rituximab	null	null	318	56.2	6.5	17.81	415.3	8.27	0	8.751	608.1	12.54	15.61	38.09	Decreasing	0	Negative	2.4	0	6	15088-0	TT_Wildtype	0	0	0	0	0	9.7	1	0	0	0	null	0	0	0	null	0	null	null	0	61.1	84.2	0	0	0	null	0	null	0	Progression	0	0	120	1	0	67	Stable	0	21.1	43.8	17.9	2	0	0	0	0	1
HC007-000009	IPF	73.7	Female	Black_Non-Hispanic	Former_Smoker	71.6	null	Other	21.9	157	2,023	8	CB03.10	Probable_UIP	18.6	0	0	4.3	2.5	Bilateral_Basal	26.2	0	0	2.61	21.4	GE	2	74.3	2.42	-10.2	68.7	-6.24	76.1	0.361	0.864	167	80.1	92	1	4.1	Fast_Decliner	5	0	19876-2	19911-7	Trial_Drug	0	0	6	0.669	0	0	null	null	0	0	0	null	Placebo	Phase_II	321	107.5	51.3	9.18	2,393.7	5.6	0	4.503	993.5	8.21	14.74	45.86	Increasing	0	Negative	10.3	0	0.2	15088-0	TT_Wildtype	0	0	0	0	0	13.8	0	0	0	0	null	0	0	0	null	0	null	null	1	29.6	56.6	1	1	1	1	0	0.7	0	Progression	0	0	29.8	1	1	12	Stable	3	50.4	38.7	54.6	7	0	0	1	0	1
HC007-000010	IPF	77.9	Male	East_Asian	Former_Smoker	34.4	null	Europe	29.7	186.1	2,011	60	CB03.10	UIP	45.6	1	7.8	11.3	3.1	Bilateral_Basal	42.6	0	0	3.17	42	Philips	0.79	56.9	2.27	-181.3	41.5	-1.97	55.7	0.319	0.81	215	81.2	94.5	0	0	Stable	5	0	19876-2	19911-7	Untreated	0	0	1.8	0.662	0	0	null	null	0	0	0	Mycophenolate	null	null	1,278	225.3	47.1	6.13	241.9	5.34	0	9.923	315.2	9.25	15.8	27.63	Stable	1	Negative	10	0	1	15088-0	GG_Hom	1	0	0	0	1	62.6	0	0	1	1	Infection_Viral	1	0	0.682	null	1,000	16.5	-279.8	0	49.8	51.9	0	0	0	null	0	null	1	Progression	1	0	58.2	1	0	7	None_to_Exertional	2	32.3	31.2	55.4	2	0	1	0	1	1
HC007-000011	IPF	70.7	Female	East_Asian	Former_Smoker	53.5	Mold	Europe	27.6	161.8	2,019	60	CB03.10	UIP	53.6	1	6.1	6.4	2.2	Bilateral_Basal	37.7	1	0	2.86	59.7	Philips	0.84	89.1	3.01	-264.4	32.7	-3.24	65.6	0.404	0.871	208	90.9	90.5	0	0	Slow_Decliner	6	2.1	19876-2	19911-7	Pirfenidone	2,403	0	0.6	0.761	0	0	null	null	85.4	0	0	null	null	null	1,946	166.5	13.9	10.19	638.4	4.25	1	1.861	323.3	21.43	12.48	15.33	Increasing	0	1:160+	6	0	0.9	15088-0	TT_Wildtype	0	0	0	0	0	15.7	0	0	1	1	Drug_Reaction	1	0	0.437	null	1,000	23.6	-325.2	0	52.4	69.8	0	0	0	null	0	null	1	Stable	1	1	44.7	1	1	28	Exertional_to_Continuous	3	54.6	22.2	57.6	5	1	0	1	1	0
HC007-000012	COP	59.6	Male	White_Non-Hispanic	Former_Smoker	34	Wood_Dust	North_America	34.8	174.8	2,021	56	CB03.12	Alternative_Dx	10.5	0	0	46.4	1.5	Bilateral_Basal	13.6	0	0	5.83	10.2	Siemens	0.94	101.8	3.92	-135	58.3	-4.43	66.9	0.315	0.693	384	82.8	91.1	0	0	Improver	0	0	19876-2	19911-7	Untreated	0	0	6.2	0.777	0	0	null	null	0	1	52	Mycophenolate	null	null	270	57.7	66.2	10.6	295.5	5.83	0	5.875	693.2	11.31	27.52	21.35	Stable	0	Negative	20	0	0.8	15088-0	TT_Wildtype	0	0	0	0	0	33	0	0	0	0	null	0	0	0	null	0	null	null	0	46.1	46.9	0	0	0	null	0	null	0	Progression	0	0	5.9	1	0	38	Exertional_to_Continuous	2	35.6	18.9	15.4	2	0	0	0	1	1
HC007-000013	HP	65.4	Female	White_Non-Hispanic	Never	0	Mold	East_Asia	27.5	163.1	2,017	10	CA22	Probable_UIP	30.2	0	0	17.1	2.6	Bilateral_Basal	37.9	1	0	5.94	34.1	Siemens	1.68	56.3	1.71	-69.6	52.8	-2.01	76.7	0.438	0.871	394	83.6	98.7	0	0	Stable	5	0	19876-2	19911-7	Untreated	0	0	3.8	0.752	0	0	null	null	0	1	8	null	null	null	1,394	34.4	36.4	15.45	175.6	5.29	0	8.17	302.5	5.52	11.02	17.68	Increasing	1	Negative	2.4	0	0.3	15088-0	TG_Het	0	0	0	0	0	41.4	0	0	0	0	null	0	0	0	null	0	null	null	0	45.9	72.1	0	0	0	null	0	null	1	Progression	0	0	19.1	1	1	11	Stable	1	22.4	80	77.5	5	0	1	1	1	1
HC007-000014	CTD-ILD	51.3	Female	White_Non-Hispanic	Former_Smoker	24.5	null	East_Asia	23.5	160.6	2,016	33	CB03.1Z	Probable_UIP	26.2	0	0	6	0.3	Bilateral_Basal	48.4	0	0	1.89	20.6	Philips	1.26	86	3	1.5	70.8	-2.88	67.3	0.393	0.9	593	87.5	98.1	0	0	Stable	1	0	19876-2	19911-7	Untreated	0	0	4.4	0.902	0	0	null	null	0	0	0	null	null	null	636	76.6	26.1	14.24	722.4	4.83	0	8.593	269.5	11.88	22.15	23.93	Increasing	0	1:160+	9.5	0	2.3	15088-0	TT_Wildtype	0	0	0	0	0	13.6	0	0	0	0	null	0	0	0	null	0	null	null	0	17.1	30	0	0	0	null	0	null	0	Stable	0	0	23.2	1	0	12	Exertional_to_Continuous	3	31.2	54.1	39.1	2	0	0	0	1	0
HC007-000015	IPF	76.4	Female	White_Non-Hispanic	Former_Smoker	37.1	Wood_Dust	North_America	26.2	155.9	2,011	38	CB03.10	UIP	48.6	1	8.3	8	1.7	Diffuse	57.9	0	0	0	56.7	Philips	1.36	63.6	1.96	-146.6	63	-2.22	72.9	0.44	0.846	321	82.3	99	1	4.5	Fast_Decliner	5	0	19876-2	19911-7	Pirfenidone	2,403	0	0.5	0.785	0	1	Death	14.6	141.4	0	0	Mycophenolate	null	null	347	272.6	44.2	18.27	1,812.4	6.03	0	5	599.2	6.24	21.56	35.09	Stable	0	Negative	16.8	0	5.4	15088-0	TT_Wildtype	0	0	0	0	1	5.7	0	0	0	0	null	0	0	0	null	0	null	null	0	42.8	76	0	0	0	null	0	null	0	Progression	0	0	3	1	0	25	Stable	3	49.9	67	22.1	4	0	1	1	1	0
HC007-000016	IPF	48.7	Male	White_Non-Hispanic	Former_Smoker	40.7	null	Other	20.5	174.4	2,013	18	CB03.10	UIP	29.9	0	0	1.7	2.7	Bilateral_Basal	30	0	0	1.71	31.4	Siemens	1.32	70.9	2.49	-219	40.6	-5.54	72.4	0.235	0.822	403	92.5	95.4	0	0	Slow_Decliner	2	0	19876-2	19911-7	Nintedanib	0	300	7.1	0.808	1	1	Hepatotoxicity	22.3	191.7	0	0	Mycophenolate	null	null	1,859	148.8	36.4	4.03	418.1	5.14	0	2.167	329.9	5.66	11.26	24.23	Increasing	0	Negative	4.3	0	4	15088-0	TT_Wildtype	0	1	0	1	0	43.1	0	0	0	0	null	0	0	0	null	0	null	null	0	41.9	49.8	0	0	0	null	0	null	1	Stable	1	1	61.9	1	0	35	Exertional_to_Continuous	2	37.2	28.3	53.8	3	1	0	0	1	1
HC007-000017	HP	56	Female	White_Non-Hispanic	Former_Smoker	20.9	null	North_America	29.6	154.8	2,021	37	CA22	Probable_UIP	11.2	1	7.7	28.7	0.8	Bilateral_Basal	21.8	1	0	1.32	13.4	GE	1.91	101.5	3.52	-144.9	35	-1.54	63.8	0.275	0.872	375	80.7	95.9	0	0	Improver	3	0	19876-2	19911-7	Trial_Drug	0	0	1.3	0.652	0	0	null	null	0	1	35	null	GLPG1205	Phase_III	748	66.4	25.1	7.4	178.6	7.55	0	11.098	1,048.6	10.55	14.2	24.49	Increasing	1	1:160+	1.6	0	1.6	15088-0	TT_Wildtype	0	1	1	0	0	38.7	0	0	0	0	null	0	0	0	null	0	null	null	0	54.6	63.5	0	0	0	null	0	null	1	Transplant	0	0	87.6	0	1	0	Exertional_to_Continuous	3	26.7	39.1	69.2	4	1	0	0	0	0
HC007-000018	IPF	47.1	Female	White_Non-Hispanic	Former_Smoker	32.7	Wood_Dust	East_Asia	30.6	156.9	2,014	60	CB03.10	Indeterminate	25.9	1	13.1	3.8	1.8	Bilateral_Basal	29.3	1	0	4.95	19.1	Siemens	0.55	57.9	1.41	-100.8	30.8	-3.51	62.3	0.458	0.896	395	87	93.5	1	1.7	Stable	4	4.6	19876-2	19911-7	Pirfenidone	2,403	0	0.5	0.779	1	0	null	null	114.9	0	0	Mycophenolate	null	null	546	170.3	18.3	10.53	503.1	5.3	0	4.781	321.7	4.93	16.43	18.98	Decreasing	0	1:40-1:80	1.1	0	4.9	15088-0	TT_Wildtype	0	0	0	0	0	9.6	0	0	0	0	null	0	0	0	null	0	null	null	0	53.5	69.7	0	0	0	null	0	null	0	Stable	0	0	16.2	0	0	0	None_to_Exertional	2	72.3	26.7	67.5	3	0	1	0	1	0
HC007-000019	CTD-ILD	37.1	Female	White_Non-Hispanic	Former_Smoker	24	null	Other	40.3	166	2,010	23	CB03.1Z	UIP	10.3	0	0	15.9	0	Bilateral_Basal	31.3	0	1	5.13	5.1	Philips	0.74	90.7	2.84	-58.5	21.5	-1.33	58.6	0.337	0.851	374	83.3	92.9	1	1.2	Fast_Decliner	3	2.1	19876-2	19911-7	Untreated	0	0	10.2	0.787	0	0	null	null	0	1	38	null	null	null	1,172	134.5	20.4	14.01	424.7	6.66	0	5.037	251.3	8.36	32.14	34.21	Increasing	0	Negative	9.8	0	0.5	15088-0	TT_Wildtype	0	1	0	0	0	24.8	1	0	0	0	null	0	0	0	null	0	null	null	0	35.9	56.1	0	0	0	null	0	null	1	Progression	0	0	108.4	1	1	10	Stable	1	18.9	37.1	85.5	2	0	0	1	0	0
HC007-000020	HP	76.4	Female	East_Asian	Former_Smoker	76.4	Wood_Dust	Europe	24.3	149	2,020	25	CA22	Probable_UIP	29.5	0	0	12.8	0	Upper_Lobe	57.3	0	0	1.03	30.5	Siemens	1.07	82.2	2.72	-176.5	53.6	-1.56	83.2	0.292	0.856	464	87.8	96.6	0	0	Slow_Decliner	5	0	19876-2	19911-7	Trial_Drug	0	0	0.5	0.678	0	0	null	null	0	0	0	null	Pamrevlumab	Phase_III	1,735	21.3	6.1	31.41	2,428.1	6.62	0	22.909	444.4	11.44	14.19	29.49	Increasing	1	Negative	62.4	0	0.6	15088-0	TG_Het	0	0	0	0	0	51.6	1	0	0	0	null	0	0	0	null	0	null	null	0	19.2	38.7	0	0	0	null	0	null	0	Progression	0	0	15.6	1	0	69	Stable	2	66.8	68.3	35.5	3	0	0	0	0	0
HC007-000021	CTD-ILD	65.7	Female	White_Non-Hispanic	Former_Smoker	33.4	null	North_America	26.1	170.9	2,019	39	CB03.1Z	Indeterminate	12	0	0	4.5	1.4	Diffuse	23.3	0	0	1.62	20.1	Philips	1.23	70.5	2.22	-82.6	57.8	-2.13	63.8	0.368	0.919	260	84.5	98.1	0	0	Stable	4	0	19876-2	19911-7	Untreated	0	0	0.5	0.815	0	0	null	null	0	1	62	Mycophenolate	null	null	269	126.1	11.7	6.76	644.2	7.04	0	6.411	604.7	21.22	70.07	9.79	Increasing	0	Negative	3.9	0	0.4	15088-0	TG_Het	0	0	0	0	0	34.1	0	0	0	0	null	0	0	0	null	0	null	null	0	22.8	43.6	0	0	0	null	0	null	0	Transplant	0	0	31.9	1	1	22	None_to_Exertional	2	63.6	38.4	9.9	5	0	0	0	0	0
HC007-000022	IPF	59.8	Female	White_Non-Hispanic	Never	0	Bird_Antigen	Europe	24.5	166.4	2,010	23	CB03.10	UIP	33.8	0	0	6.2	2.8	Diffuse	51.1	0	0	0.09	39.8	Philips	0.67	76.6	3.14	-239.6	31.7	-3.72	72.6	0.395	0.866	97	86.9	96.4	0	0	Slow_Decliner	3	0	19876-2	19911-7	Trial_Drug	0	0	6.2	0.893	0	0	null	null	0	0	0	Rituximab	Placebo	Phase_II	1,474	71.6	93.7	7.73	142.6	4.62	0	4.431	557.9	11.24	22.36	10.07	Stable	0	1:40-1:80	14	0	2	15088-0	TT_Wildtype	0	0	0	0	0	18.6	0	0	1	1	Idiopathic	1	1	0.528	Complete	500	20.7	-231	0	58.9	70.1	0	0	0	null	0	null	0	AE	1	1	55.7	1	0	21	Exertional_to_Continuous	1	59.2	45	43.5	2	1	0	1	1	1
HC007-000023	SR-ILD	45	Male	East_Asian	Current	24.6	null	North_America	28.6	167.8	2,010	60	CB03.13	Probable_UIP	23.5	0	0	6.1	0.1	Bilateral_Basal	30.2	1	0	3.48	26.5	Philips	1.84	78.5	3.52	-97.3	37.8	-2.08	65.8	0.371	0.772	400	93.1	91.5	1	4.2	Slow_Decliner	1	1.5	19876-2	19911-7	Untreated	0	0	17.1	0.606	0	1	GI_Intolerance	13.1	0	1	5	null	null	null	692	39.6	11.5	8.92	1,040.3	7.76	0	4.275	650.2	3.92	18.87	20.78	Decreasing	0	Negative	0.4	0	2.4	15088-0	TT_Wildtype	0	0	0	0	0	13.4	0	1	0	0	null	0	0	0	null	0	null	null	0	41.1	62	0	0	0	null	0	null	0	Stable	0	0	23.6	1	1	15	None_to_Exertional	0	57	33.7	0	6	0	0	0	0	1
HC007-000024	NSIP	35	Male	East_Asian	Former_Smoker	39.7	null	East_Asia	29.5	169.7	2,011	18	CB03.11	UIP	5.6	0	0	38.8	0	Bilateral_Basal	37.3	0	0	3.11	1.5	Canon	1.52	53.1	2.17	-75.8	57.7	-1.28	82.9	0.408	0.896	189	83.6	95.2	0	0	Stable	2	0	19876-2	19911-7	Untreated	0	0	0.7	0.845	0	0	null	null	0	0	0	null	null	null	572	70.4	5.1	7.59	663.7	4.85	0	8.909	302.7	4.23	23.42	39.86	Decreasing	0	1:160+	12.8	0	0.1	15088-0	TT_Wildtype	0	0	0	0	0	14.5	0	0	0	0	null	0	0	0	null	0	null	null	0	24.6	55.4	0	0	0	null	0	null	1	Progression	0	0	32.7	0	0	0	Exertional_to_Continuous	4	29.4	62.6	30.3	2	0	0	1	0	1
HC007-000025	CTD-ILD	48.5	Female	Hispanic	Former_Smoker	11.2	null	North_America	27.2	160.9	2,010	34	CB03.1Z	Indeterminate	8.6	0	0	4	2.7	Bilateral_Basal	35.4	0	0	4.86	3.9	GE	1.9	63.1	2.14	-91.5	47.9	-2.29	40.2	0.4	0.813	485	83.5	91.7	0	0	Stable	3	0	19876-2	19911-7	Untreated	0	0	1.9	0.881	0	1	Hepatotoxicity	1.7	0	0	0	Mycophenolate	null	null	418	85.5	45.7	7.07	766.5	6.56	0	3.697	987.2	19.36	8.27	43.96	Stable	0	Negative	2.2	0	0.1	15088-0	TT_Wildtype	1	0	0	0	0	36.6	0	0	0	0	null	0	0	0	null	0	null	null	0	26.1	45.5	0	0	0	null	0	null	0	Progression	0	0	60.4	0	1	0	None_to_Exertional	3	33.4	35.8	43.3	4	0	1	1	1	0
HC007-000026	IPF	90	Male	White_Non-Hispanic	Never	0	Wood_Dust	Europe	33.1	177	2,018	53	CB03.10	UIP	35.1	0	0	5.9	2.6	Diffuse	66.4	0	0	4.24	40	Philips	1.91	51.2	2.21	-110.6	46.6	-3.09	72.2	0.397	0.822	278	85.4	93	0	0	Stable	6	10.6	19876-2	19911-7	Pirfenidone	2,403	0	4.3	0.885	0	0	null	null	84.4	0	0	null	null	null	1,082	41.4	27.1	11.28	492.9	4.11	1	8.224	139.9	5.95	26.28	35.93	Stable	0	Negative	5.1	0	1.1	15088-0	TG_Het	0	0	1	0	0	56.4	0	0	0	0	null	0	0	0	null	0	null	null	0	44.8	51.3	0	0	0	null	0	null	0	Death	0	0	14	1	0	26	Stable	3	77.9	72.5	39.2	3	0	0	1	1	1
HC007-000027	IPF	71.3	Male	Hispanic	Former_Smoker	38.8	null	Other	24.3	171.1	2,011	9	CB03.10	Probable_UIP	46.9	1	10.1	2.1	2.6	Bilateral_Basal	39	0	0	4.48	55.1	Philips	1.27	65	2.74	-298.4	44.1	-2.08	50.4	0.461	0.826	231	94.4	98.9	1	2	Slow_Decliner	5	16.3	19876-2	19911-7	Pirfenidone	2,403	0	2.2	0.671	0	0	null	null	81.6	0	0	Mycophenolate	null	null	2,315	62.1	28.3	18.03	818.5	5.63	0	11.714	258.1	3.83	9.69	22.75	Decreasing	1	Negative	9	0	0.1	15088-0	TG_Het	0	0	0	0	0	35.4	0	1	1	1	Idiopathic	1	0	0.544	null	750	10.7	-364.5	1	43.5	59.9	0	1	1	1	1	0.59	0	Progression	1	1	49	1	1	12	Exertional_to_Continuous	3	62.3	40.2	65.2	5	0	0	1	1	0
HC007-000028	IPF	61.4	Female	White_Non-Hispanic	Never	0	Mold	North_America	32.6	155.2	2,018	25	CB03.10	UIP	28.2	1	13.7	7.2	1.6	Bilateral_Basal	18.8	0	0	0	32.1	Philips	1.78	94.2	2.99	-194.5	54	-4.55	73.5	0.379	0.878	587	86.6	90.4	0	0	Stable	3	0	19876-2	19911-7	Nintedanib	0	300	16.6	0.773	1	1	Progression	19.4	159.8	0	0	null	null	null	1,598	54.7	19.6	11.7	491.1	7.05	0	5.737	458	4.94	23.29	51.03	Stable	0	Negative	1.1	0	3.8	15088-0	TT_Wildtype	0	0	0	0	0	3.7	1	0	1	1	Infection_Viral	1	0	0.78	null	1,000	9.2	-96.3	0	61.9	59.2	0	0	0	null	0	null	1	AE	1	1	53.6	1	0	20	Exertional_to_Continuous	2	52.4	96.5	51.4	5	0	0	0	1	0
HC007-000029	IPF	71.7	Female	White_Non-Hispanic	Former_Smoker	39	null	North_America	30.3	165.4	2,012	22	CB03.10	UIP	59.7	1	2.8	6.8	1.9	Bilateral_Basal	38.4	0	0	1.88	74.2	GE	1.61	80.5	2.37	-277.2	41	-0.47	65.9	0.377	0.925	328	93.2	99	1	3.5	Stable	5	4.4	19876-2	19911-7	Pirfenidone	1,602	0	18	0.779	1	0	null	null	88.1	0	0	Azathioprine	null	null	311	107.5	46	7.17	262.7	6.58	0	10.943	273.7	12.15	12.97	17.09	Decreasing	0	1:160+	200	0	1.8	15088-0	TT_Wildtype	0	0	0	0	0	18.2	0	0	0	0	null	0	0	0	null	0	null	null	0	41	59.6	0	0	0	null	0	null	0	AE	1	1	20.4	1	1	40	None_to_Exertional	2	33.1	72	63.6	3	0	0	1	1	1
HC007-000030	CTD-ILD	36.3	Male	White_Non-Hispanic	Current	22	Asbestos	Europe	27.4	171.7	2,023	20	CB03.1Z	Probable_UIP	13.4	1	3.7	3.2	2.6	Diffuse	32.1	0	1	5.19	11.3	Siemens	1.04	48.2	2.09	-33.5	50.2	-6.86	47.3	0.428	0.821	340	86.1	95.6	1	3.3	Slow_Decliner	3	5	19876-2	19911-7	Untreated	0	0	0.5	0.854	0	0	null	null	0	1	41	Mycophenolate	null	null	134	55.7	75.5	9.99	372.7	7.98	0	5.805	359	8.64	11.94	20.69	Increasing	0	Negative	3.9	0	0.7	15088-0	TT_Wildtype	0	1	0	0	0	29.1	1	0	1	1	Idiopathic	1	0	0.571	Partial	500	54.4	-113.3	0	46.6	46.3	0	0	0	null	0	null	0	AE	0	0	38	1	0	26	None_to_Exertional	2	27.5	47	59.3	0	0	0	0	1	1
HC007-000031	CTD-ILD	51.4	Female	White_Non-Hispanic	Current	31.8	Mold	North_America	25.9	172.3	2,020	17	CB03.1Z	Probable_UIP	8.5	0	0	5.4	0.3	Bilateral_Basal	29.2	0	0	2.07	10.2	Canon	1.49	69.1	1.99	-115.7	27.9	-3.43	72.7	0.413	0.924	431	92.9	92.6	0	0	Fast_Decliner	4	0	19876-2	19911-7	Untreated	0	0	3	0.901	0	0	null	null	0	0	0	Rituximab	null	null	164	24	14.6	6.56	297.6	6.08	0	4.005	224.3	11.29	33.41	12.06	Stable	0	1:40-1:80	16.9	0	0.9	15088-0	TT_Wildtype	0	0	0	0	0	18	0	0	0	0	null	0	0	0	null	0	null	null	0	41.5	60.2	0	0	0	null	0	null	0	Stable	0	0	44	0	0	0	Exertional_to_Continuous	3	22.5	49.4	13.4	5	1	0	0	0	0
HC007-000032	SR-ILD	64.2	Male	White_Non-Hispanic	Former_Smoker	64.3	Metal_Dust	North_America	40.1	172.3	2,015	6	CB03.13	Probable_UIP	11.5	1	5.5	12.1	0.2	Bilateral_Basal	28.2	1	0	0	4.2	Siemens	1.93	78.2	2.72	-117	57.2	-4.31	71.1	0.326	0.83	437	89	94.2	0	0	Improver	1	0	19876-2	19911-7	Untreated	0	0	8.4	0.77	1	0	null	null	0	0	0	Mycophenolate	null	null	232	51	36.8	18.02	449.1	7.77	0	2.228	385.4	8.03	15.8	20.64	Increasing	0	Negative	49	0	1.5	15088-0	TG_Het	0	0	0	0	0	32.3	1	0	0	0	null	0	0	0	null	0	null	null	0	51.8	64.5	0	0	0	null	0	null	0	Stable	1	1	28.5	0	0	0	None_to_Exertional	3	30.9	75.4	67.6	4	0	0	0	0	1
HC007-000033	IPF	66.1	Male	White_Non-Hispanic	Former_Smoker	33.9	Mold	North_America	23.3	177.7	2,016	42	CB03.10	UIP	41.6	0	0	3	1.1	Upper_Lobe	37.9	0	0	4.9	46.8	Canon	1.65	83.4	3.84	-60.7	51.4	-4.78	64.8	0.374	0.904	438	89.8	91.9	1	3.9	Stable	3	5.1	19876-2	19911-7	Pirfenidone	2,403	0	1.4	0.89	0	0	null	null	131.6	0	0	Rituximab	null	null	707	37.8	54.3	23	354.8	4.83	0	7.135	616.6	4.7	8.91	15.94	Stable	0	Negative	11.6	0	0.1	15088-0	TT_Wildtype	0	0	0	0	0	10.7	0	0	1	1	Idiopathic	1	0	0.509	null	1,000	28.4	-133.8	0	63.1	84.1	0	0	0	null	0	null	0	Progression	1	1	22.5	1	1	23	None_to_Exertional	2	38.6	54.5	38	3	1	0	0	0	1
HC007-000034	IPF	74.9	Female	East_Asian	Former_Smoker	78	Metal_Dust	North_America	29	159.9	2,010	3	CB03.10	UIP	32.4	1	5	9	2.3	Bilateral_Basal	50.8	0	0	1.99	43	Siemens	1.56	58.3	1.64	-274.8	47.2	-2.89	66.5	0.406	0.832	203	79.8	92.4	0	0	Improver	6	17.8	19876-2	19911-7	Nintedanib	0	300	0.7	0.573	0	0	null	null	78.9	1	41	Azathioprine	null	null	874	30.7	14	4.97	248.9	5.16	0	7.226	306.5	3.34	24.29	52.93	Decreasing	0	Negative	1.9	0	3.9	15088-0	TT_Wildtype	0	0	0	0	0	22.2	0	0	1	1	Procedure	1	0	0.387	Partial	1,000	11.9	-164.4	1	53.3	66.7	0	1	0	3.4	1	8.1	0	Progression	1	0	71	1	0	1	Stable	2	46.5	60	57.6	3	0	0	1	0	1
HC007-000035	IPF	70.4	Female	White_Non-Hispanic	Former_Smoker	26.3	null	Europe	23.6	158.7	2,010	60	CB03.10	Probable_UIP	34.2	0	0	7.7	2.8	Peripheral	25.6	0	0	5.43	32.4	GE	0.83	47.7	1.52	-218.9	80.6	-5.75	70.3	0.345	0.79	381	79.1	94.2	0	0	Fast_Decliner	6	0	19876-2	19911-7	Pirfenidone	2,403	0	1	0.947	0	1	GI_Intolerance	22.2	42.1	0	0	null	null	null	1,146	135.4	74.3	12.36	280.5	5.98	0	10.9	241	5.38	10.09	47.97	Stable	0	Negative	9.2	0	0.8	15088-0	TT_Wildtype	1	0	0	0	0	54.9	0	0	1	1	Idiopathic	1	0	0.661	null	500	12.6	-351.2	0	65.7	90	0	0	0	null	0	null	0	Progression	0	0	8.7	1	1	38	Exertional_to_Continuous	3	65.2	90.3	64	4	0	0	0	0	0
HC007-000036	IPF	73.7	Male	White_Non-Hispanic	Former_Smoker	21.2	Bird_Antigen	Europe	36.8	182.9	2,017	14	CB03.10	UIP	38.1	0	0	15.5	2.1	Bilateral_Basal	26.4	0	0	3.16	46.1	Canon	1.75	69	2.67	-121.9	52.6	0.8	84.5	0.348	0.935	302	92.4	93	1	3.4	Improver	5	0	19876-2	19911-7	Nintedanib	0	300	1.9	0.737	1	0	null	null	167.2	0	0	null	null	null	1,172	108	54.2	7.47	329.2	6.99	0	10.288	322.9	8.68	28.34	25.32	Stable	0	1:160+	0.9	0	0.3	15088-0	TG_Het	0	0	0	0	0	20.1	0	0	0	0	null	0	0	0	null	0	null	null	1	48.5	66.1	0	1	1	4.7	1	12.02	0	Progression	0	0	41.6	1	0	15	None_to_Exertional	2	82	52.1	31.3	0	1	0	0	0	0
HC007-000037	IPF	60.1	Female	White_Non-Hispanic	Current	20.5	null	North_America	32.1	159.3	2,010	12	CB03.10	UIP	39.3	0	0	6.4	4	Upper_Lobe	44.6	0	0	2.62	50.4	Philips	1.08	80.2	2.27	-133.9	47.5	-6.2	63.6	0.297	0.785	243	92.3	91.2	0	0	Slow_Decliner	3	8.4	19876-2	19911-7	Pirfenidone	2,403	0	6.2	0.869	0	1	Death	28.7	128.9	0	0	null	null	null	1,160	37.3	8.2	11.38	66.5	5.03	0	20.914	965.6	4.52	16.34	30.98	Increasing	0	Negative	5.5	0	0.9	15088-0	TT_Wildtype	0	0	0	0	0	15.7	1	0	0	0	null	0	0	0	null	0	null	null	0	23	44.8	0	0	0	null	0	null	0	Progression	1	1	59.6	1	0	14	Stable	1	70.6	6	34	4	0	0	0	1	1
HC007-000038	IPF	76	Male	White_Non-Hispanic	Former_Smoker	77	Asbestos	Europe	24	171.4	2,018	14	CB03.10	Probable_UIP	48.4	0	0	1.9	1.4	Upper_Lobe	46	0	0	6.06	49.8	GE	1.44	74.2	2.8	-260.2	58	-5.4	82.2	0.22	0.781	335	98	93.3	1	2.3	Slow_Decliner	4	0	19876-2	19911-7	Untreated	0	0	0.5	0.657	0	0	null	null	0	0	0	Mycophenolate	null	null	2,672	31.1	79.5	10.56	830.5	6.77	0	4.269	960	13.35	9.88	18.14	Increasing	0	Negative	61.1	0	3	15088-0	TT_Wildtype	0	0	0	0	0	10.7	1	0	0	0	null	0	0	0	null	0	null	null	0	32.1	42	0	0	0	null	0	null	0	Transplant	0	0	70	1	1	32	Exertional_to_Continuous	3	20.8	51.5	52.9	4	0	1	1	0	0
HC007-000039	IPF	83.3	Male	White_Non-Hispanic	Former_Smoker	49.8	null	North_America	30.2	170	2,015	60	CB03.10	UIP	36.6	1	6.7	11.5	2.5	Bilateral_Basal	46.9	1	0	0.46	42.6	Siemens	1.52	54.1	2.56	-59.3	83.8	-5.59	67.5	0.358	0.745	158	79.6	90.1	1	6	Fast_Decliner	5	0	19876-2	19911-7	Nintedanib	0	300	0.7	0.976	0	0	null	null	159.9	0	0	null	null	null	371	62.7	8.6	5.64	451.8	6.12	0	7.49	319	4.95	22.84	6.9	Decreasing	0	Negative	1.5	1	0.3	15088-0	TT_Wildtype	0	0	0	0	0	7.7	1	0	0	0	null	0	0	0	null	0	null	null	0	51.9	61.4	0	0	0	null	0	null	0	Stable	1	0	8.5	0	0	0	Exertional_to_Continuous	1	29.9	71.5	39.5	4	1	0	1	0	1
HC007-000040	HP	48.4	Male	White_Non-Hispanic	Never	0	null	North_America	28.8	176.2	2,011	15	CA22	Alternative_Dx	12.2	1	4	20.7	0.9	Diffuse	26.8	0	0	6.21	21.3	Siemens	1.27	105.6	4.79	-62.5	62	-3.1	86.1	0.388	0.896	448	89.4	90.2	1	1.1	Slow_Decliner	0	0	19876-2	19911-7	Untreated	0	0	3.2	0.856	0	0	null	null	0	1	33	null	null	null	1,137	30.1	12.8	20.17	190.5	6.97	0	4.005	636.4	3.58	20.26	16.76	Increasing	1	Negative	3	0	0.3	15088-0	TG_Het	0	0	0	0	0	17.7	0	0	0	0	null	0	0	0	null	0	null	null	0	39.1	40.9	0	0	0	null	0	null	1	Stable	0	0	86.6	1	0	8	Stable	1	26.4	54.3	96.7	3	1	0	1	0	1
HC007-000041	IPF	58.1	Male	White_Non-Hispanic	Former_Smoker	57.5	Metal_Dust	Europe	24.8	179.5	2,017	28	CB03.10	Indeterminate	31.8	0	0	9.6	3	Bilateral_Basal	42.3	0	0	1.86	36.1	Siemens	0.75	68.2	2.87	-121	18	-1.47	64.7	0.314	0.91	302	81.9	90.2	1	5	Fast_Decliner	3	14.7	19876-2	19911-7	Pirfenidone	1,602	0	4.7	0.814	0	1	GI_Intolerance	20.4	69.5	0	0	Mycophenolate	null	null	1,511	57.7	38.4	10.22	562.3	4.6	0	10.57	440.2	8.17	7.03	35.66	Increasing	0	Negative	75.5	0	2	15088-0	TG_Het	0	0	0	0	0	37.9	0	0	0	0	null	0	0	0	null	0	null	null	0	42	45.9	0	0	0	null	0	null	0	Stable	1	1	19.6	1	0	40	None_to_Exertional	2	63.4	24.8	52.3	5	0	0	1	0	0
HC007-000042	NSIP	79	Female	East_Asian	Former_Smoker	47.4	null	North_America	31.4	168.2	2,017	4	CB03.11	Alternative_Dx	4.2	1	3.3	29.9	0.6	Bilateral_Basal	45.3	0	0	3.54	8.6	GE	1.55	77.5	2.24	-156.6	64.9	-2.45	58.7	0.463	0.842	315	83.3	99	0	0	Fast_Decliner	4	0	19876-2	19911-7	Untreated	0	0	0.5	0.385	0	0	null	null	0	0	0	null	null	null	248	69.6	51.1	8.71	209.1	5.96	0	3.469	1,095.4	11.95	16.03	30.54	Increasing	0	1:160+	6.6	0	0.8	15088-0	TT_Wildtype	1	0	0	0	0	36.1	0	1	0	0	null	0	0	0	null	0	null	null	0	32.3	46.1	0	0	0	null	0	null	0	Progression	0	0	110.9	1	1	11	None_to_Exertional	3	57.9	46.3	21.8	0	0	1	0	0	0
HC007-000043	CTD-ILD	52.7	Male	Black_Non-Hispanic	Current	34.1	null	Europe	29.5	169.3	2,020	60	CB03.1Z	Probable_UIP	25.6	0	0	3.6	1	Bilateral_Basal	31.3	0	0	3.56	19.3	GE	0.87	62.1	2.1	-78.5	43.9	-0.56	52.6	0.317	0.761	347	84.5	95.2	0	0	Slow_Decliner	2	2.7	19876-2	19911-7	Untreated	0	0	7.7	0.659	0	0	null	null	0	0	0	Azathioprine	null	null	872	80.1	24	11.68	209.1	6.37	0	10.467	509.8	17.22	18.53	20.17	Stable	0	1:40-1:80	2.8	0	0.1	15088-0	TT_Wildtype	0	0	0	0	0	10.7	0	0	0	0	null	0	0	0	null	0	null	null	0	59.3	72.8	0	0	0	null	0	null	0	Progression	0	0	9.7	1	0	14	None_to_Exertional	2	35	77.7	106.2	6	0	1	0	1	0
HC007-000044	IPF	81	Male	White_Non-Hispanic	Former_Smoker	7.1	null	Other	28.6	179.7	2,012	60	CB03.10	UIP	56.9	1	8	15.7	2.1	Bilateral_Basal	48.9	0	0	2.3	65.6	Siemens	0.9	89.9	4.01	-127.8	19.2	-5.15	67.5	0.435	0.82	314	88.9	95.8	1	2.4	Slow_Decliner	5	5.7	19876-2	19911-7	Nintedanib	0	300	0.6	0.863	0	0	null	null	170.2	0	0	Azathioprine	null	null	1,558	81.8	13.4	7.13	462.7	6.27	0	3.889	387.2	3.65	18.11	35.51	Stable	0	1:40-1:80	13	0	5.8	15088-0	TT_Wildtype	0	0	0	0	0	24.6	0	0	0	0	null	0	0	0	null	0	null	null	0	60.4	76.6	0	0	0	null	0	null	0	Progression	0	0	7.8	1	0	39	None_to_Exertional	1	42	19.6	61.1	4	0	0	0	1	0
HC007-000045	NSIP	57.7	Male	White_Non-Hispanic	Former_Smoker	30.2	Metal_Dust	Europe	27.3	176.6	2,017	3	CB03.11	Alternative_Dx	21.3	0	0	40.5	0.6	Bilateral_Basal	36.5	0	0	1.6	26	GE	0.69	84.3	3.34	-78.9	85.2	-2.18	56.9	0.405	0.802	468	83.7	94	1	2.7	Slow_Decliner	0	0	19876-2	19911-7	Pirfenidone	1,602	0	7.8	0.683	0	0	null	null	130.9	0	0	Azathioprine	null	null	582	41.7	18	10.06	1,197	5.37	0	9.582	1,366.4	16.64	15.27	19.39	Increasing	0	Negative	4.7	0	3.4	15088-0	TT_Wildtype	0	0	0	0	0	11.5	0	0	0	0	null	0	0	0	null	0	null	null	0	39.3	46.8	0	0	0	null	0	null	0	Progression	1	1	51.2	0	1	0	Stable	4	48.1	13.6	51	3	0	0	1	0	0
HC007-000046	CTD-ILD	72.5	Male	Hispanic	Former_Smoker	26.7	Wood_Dust	Europe	29.7	161.3	2,021	13	CB03.1Z	Indeterminate	7.8	1	13.5	21.8	1	Bilateral_Basal	26.6	0	0	2.42	1.9	Canon	1.43	79.7	3.01	-142.2	81.7	-4.11	87.7	0.511	0.758	256	87.2	95.5	1	0.5	Fast_Decliner	3	0	19876-2	19911-7	Nintedanib	0	300	4.2	0.861	0	0	null	null	60.2	0	0	Rituximab	null	null	110	69.6	16.4	4.4	424.9	4.69	0	12.477	233.5	8.96	22.15	13.86	Stable	0	Negative	0.3	0	10	15088-0	TT_Wildtype	1	0	0	0	0	36.1	0	0	1	1	Idiopathic	1	1	0.571	null	1,000	24.3	-321	0	39.4	53.8	0	0	0	null	0	null	0	Progression	0	0	87.1	1	1	32	Stable	2	54.1	31.3	91.5	5	0	0	0	1	0
HC007-000047	IPF	68.3	Female	Other	Current	40.3	null	North_America	28.7	171.9	2,013	6	CB03.10	Probable_UIP	26.5	0	0	4.9	1.4	Peripheral	54.9	0	0	1.07	24.3	Philips	0.68	49.3	1.54	-164.3	35.5	-3.04	55.8	0.412	0.791	294	91.2	97.5	1	2	Fast_Decliner	6	0	19876-2	19911-7	Pirfenidone	1,602	0	2.4	0.753	1	0	null	null	91.2	0	0	Azathioprine	null	null	2,356	143.8	43.5	3.39	164.3	2.81	1	2.381	557.5	5.99	20.65	35.51	Stable	0	1:160+	1.6	0	2.7	15088-0	TT_Wildtype	1	0	0	0	0	29.3	0	0	0	0	null	0	0	0	null	0	null	null	0	57.3	81.1	0	0	0	null	0	null	0	Stable	0	0	97.2	0	1	0	None_to_Exertional	3	66.6	70.9	60	6	1	0	0	1	1
HC007-000048	IPF	69.6	Male	White_Non-Hispanic	Former_Smoker	54.1	Mold	North_America	27.8	163.5	2,021	60	CB03.10	UIP	33.6	1	3.1	7.7	2.4	Upper_Lobe	20.4	0	0	7.32	40	GE	1.02	89.7	3.67	13.4	35.6	-1.28	58.3	0.293	0.85	309	92.6	95.2	1	1.1	Fast_Decliner	3	0	19876-2	19911-7	Pirfenidone	2,403	0	0.5	0.667	0	1	Progression	1	57.6	0	0	null	null	null	1,406	20	16	6.79	240.7	6.84	0	2.696	1,160.1	11.48	16.65	18.07	Stable	0	Negative	96.4	0	5	15088-0	TG_Het	1	0	0	0	0	52.7	0	0	0	0	null	0	0	0	null	0	null	null	1	54.6	71.1	0	0	0	null	0	null	0	Progression	1	1	4.4	1	1	17	Stable	2	48	7	49.9	4	0	0	0	1	0
HC007-000049	CTD-ILD	73.8	Female	Black_Non-Hispanic	Former_Smoker	30.1	null	North_America	24.2	167.6	2,020	8	CB03.1Z	UIP	9.1	0	0	7	0.2	Bilateral_Basal	41.1	1	0	2.19	8.5	Canon	1.83	87.6	2.26	-93.9	60.6	-6.88	76.1	0.443	0.784	259	90.5	98.9	1	2.2	Stable	4	0	19876-2	19911-7	Untreated	0	0	4.1	0.58	0	0	null	null	0	0	0	Mycophenolate	null	null	796	81.1	13.2	8.45	709.2	7.82	0	6.965	710.7	16.08	14.96	40.99	Increasing	0	1:40-1:80	12.1	0	2.8	15088-0	TT_Wildtype	0	0	0	0	0	26.7	0	0	0	0	null	0	0	0	null	0	null	null	0	22.4	35.7	0	0	0	null	0	null	0	AE	0	0	23.5	0	1	0	Stable	1	40.5	50.4	10.4	2	0	0	1	1	0
HC007-000050	IPF	63.4	Female	Black_Non-Hispanic	Former_Smoker	48.3	Mold	East_Asia	36.3	175.4	2,016	49	CB03.10	UIP	45.7	1	6.9	6.6	3.3	Bilateral_Basal	48.8	0	0	5.63	55.8	GE	1.18	88.3	2.32	-132.9	35.8	0.48	84.6	0.482	0.838	345	89.3	93.9	1	0.5	Improver	3	0	19876-2	19911-7	Pirfenidone	2,403	0	1.6	0.6	0	0	null	null	103.3	0	0	Mycophenolate	null	null	112	32.9	6.8	4.58	475.3	2.99	1	6.534	261.4	3.53	17.45	9.04	Increasing	0	1:40-1:80	47.3	0	0.7	15088-0	TT_Wildtype	0	0	0	0	0	19.9	1	0	0	0	null	0	0	0	null	0	null	null	0	50.2	65.5	0	0	0	null	0	null	1	Progression	1	1	4.8	1	0	19	None_to_Exertional	2	51.7	57.9	0	1	0	0	0	1	0

End of preview. Expand in Data Studio

YAML Metadata Warning:The task_categories "survival-analysis" is not in the official list: text-classification, token-classification, table-question-answering, question-answering, zero-shot-classification, translation, summarization, feature-extraction, text-generation, fill-mask, sentence-similarity, text-to-speech, text-to-audio, automatic-speech-recognition, audio-to-audio, audio-classification, audio-text-to-text, voice-activity-detection, depth-estimation, image-classification, object-detection, image-segmentation, text-to-image, image-to-text, image-to-image, image-to-video, unconditional-image-generation, video-classification, reinforcement-learning, robotics, tabular-classification, tabular-regression, tabular-to-text, table-to-text, multiple-choice, text-ranking, text-retrieval, time-series-forecasting, text-to-video, image-text-to-text, image-text-to-image, image-text-to-video, visual-question-answering, document-question-answering, zero-shot-image-classification, graph-ml, mask-generation, zero-shot-object-detection, text-to-3d, image-to-3d, image-feature-extraction, video-text-to-text, keypoint-detection, visual-document-retrieval, any-to-any, video-to-video, other

HC-RES-007 — Pulmonary Fibrosis (ILD) Synthetic Dataset (Sample)

XpertSystems.ai · Synthetic Data Factory · Respiratory Vertical

The seventh SKU in the XpertSystems Respiratory vertical: a deep, disease-specific synthetic cohort for interstitial lung disease (ILD) and pulmonary fibrosis, spanning six subtypes — IPF, hypersensitivity pneumonitis (HP), CTD-ILD, NSIP, COP, and SR-ILD. Where HC-RES-006 covers mixed-cohort pulmonary-function monitoring, this SKU drills into fibrosis: HRCT imaging (UIP patterns, honeycombing, ground-glass, traction bronchiectasis, AI fibrosis score), PFT with GAP/CPI indices, antifibrotic treatment (pirfenidone, nintedanib, trial drugs), fibrosis biomarkers (KL-6, SP-D, MMP-7, CCL18, telomere length), genetics (MUC5B rs35705950, TERT/TERC, surfactant mutations), acute exacerbations, lung transplant (LAS, CLAD, post-tx survival), and clinical outcomes.

This repository contains a 500-row, single-seed sample. The full commercial product scales to 15,000+ patients with CSV / Parquet / JSON / FHIR delivery and ILD-subtype filtering.

SKU: HC-RES-007
Sample size: 500 patients × 131 columns
License (sample): CC-BY-NC-4.0 — commercial license available for the full product
Contact: pradeep@xpertsystems.ai · https://xpertsystems.ai

Validation

This sample passes XpertSystems Grade A+ validation (overall 10.000 / 10) with deterministic reproduction across all six canonical seeds [42, 7, 123, 2024, 99, 1].

This is the cleanest engine in the Respiratory vertical: it passes its own built-in 28/28-check benchmark suite at 100% (subtype prevalence, demographics, HRCT, PFT, treatment, biomarkers, genetics, acute exacerbation, transplant, outcomes). Validation philosophy emphasizes structural identities over distribution-fit tests — anchored by IPF-vs-non-IPF severity gradients (IPF has lower DLCO, higher 5-year mortality, and higher KL-6).

Calibration anchors

Metric	Sample value	Target range	Source
IPF prevalence	49.8%	45–55%	IPF-PRO registry (~50%)
Mean FVC % predicted	74.1%	65–80%	CAPACITY / ASCEND
Mean DLCO % predicted	53.1%	48–63%	CAPACITY / ASCEND
Mean 6MWD	348 m	300–380	IPF functional literature
Mean FVC decline	~-125 mL/yr	-200 to -80	INPULSIS
Antifibrotic adherence	76%	70–88%	IPF-PRO
Mean serum KL-6	~1220 U/mL	500–1600	Fibrosis biomarker literature
MUC5B TG/GG carrier	33%	28–40%	MUC5B rs35705950 (OR ~6.8 IPF)
5-year all-cause mortality	~36%	28–42%	IPF/ILD survival
DLCO gradient (non-IPF − IPF)	+7.5	≥2	Diffusion-defect severity ordering
Mortality gradient (IPF − non-IPF)	+0.25	≥0.08	Severity ordering
KL-6 gradient (IPF − non-IPF)	+640 U/mL	≥150	Fibrosis biomarker
Column count	131	≥124	Schema completeness (9 modules)

Observed IPF vs non-IPF (DLCO% / 5-yr mortality / KL-6): IPF 50.1 / 0.50 / 1539 vs non-IPF 57.8 / 0.26 / 904.

Schema highlights by module (131 columns)

Demographics. ILD subtype, ICD-11, subtype-specific age & sex distributions, ethnicity, smoking & pack-years, occupational exposure (asbestos/bird/mold/metal/wood), region, BMI, height, diagnosis year, follow-up.

HRCT imaging. Pattern (UIP / probable / indeterminate / alternative), fibrosis extent, honeycombing (flag & extent), ground-glass, traction bronchiectasis, distribution, reticulation, air trapping & mosaic (HP-predominant), annual progression, AI fibrosis score, platform, slice thickness.

Pulmonary function. FVC (% predicted, absolute, decline), DLCO (baseline & decline), TLC, RV/TLC, FEV1/FVC, 6MWD & SpO2 nadir, supplemental O2, FVC response category, GAP index, composite physiologic score.

Antifibrotic treatment. Treatment arm (pirfenidone / nintedanib / untreated / trial), dosing, start timing, adherence, dose reduction, discontinuation (reason & timing), FVC treatment effect, corticosteroids, immunosuppressants, trial drug & phase.

Biomarkers. KL-6, SP-D, CA19-9, MMP-7, CXCL13, telomere length & short-telomere flag, LPA, CCL18, TNF-α, TGF-β1, periostin, biomarker trend, HP antigen IgG, ANA/RF/anti-CCP, antigen exposure.

Genetics. MUC5B rs35705950 genotype, TERT/TERC/SFTPC/SFTPB/ABCA3 mutations, familial IPF, genetic risk score, telomere syndrome.

Acute exacerbation. AE flag & count, trigger, hospitalization/ICU/ventilation, 90-day mortality probability, steroid response, methylprednisolone dose, cyclophosphamide, time-to-first, post-AE FVC decline.

Lung transplant. Listing, lung allocation score (baseline & 12m), waitlist mortality, transplant performed, bilateral, timing, primary graft dysfunction, CLAD, post-transplant survival, contraindication.

Clinical outcomes. Primary annual outcome, 5-year all-cause & respiratory mortality, overall survival, hospitalization, O2 progression, PRO scores (mMRC, SGRQ, K-BILD, UCSD SOBQ), comorbidity index, pulmonary hypertension, CPFE, GERD, OSA, CVD.

Files

hc_res_007_sample.csv — 500-patient sample (131 columns)
generate_sample_dataset_hc_res_007.py — reproducible generator + validation harness
validation_report.json / validation_report.md — full scorecard
sweep_summary.json — 6-seed determinism results

Loading

import pandas as pd
df = pd.read_csv("hc_res_007_sample.csv")
print(df[["patient_id","ild_subtype","hrct_pattern","fvc_pct_predicted_baseline",
          "dlco_pct_predicted_baseline","gap_index","treatment_arm"]].head())

from datasets import load_dataset
ds = load_dataset("csv", data_files="hc_res_007_sample.csv")

Use cases

IPF vs non-IPF ILD classification from HRCT, PFT, biomarkers, and genetics
FVC/DLCO decline and disease-progression modeling
Antifibrotic treatment-response and discontinuation analytics
GAP / composite physiologic score validation and survival modeling
Acute-exacerbation risk prediction
Lung-transplant listing and post-transplant outcome modeling
MUC5B / telomere genetics association studies
ML training where real ILD-registry data is access-restricted

Honest limitations & disclosed generator behavior

This is the most rigorously validated engine in the Respiratory vertical (28/28 internal checks, correct IPF severity gradients, textbook biomarker and genetic distributions). Standard caveats:

Cross-sectional registry-style table. Each row is one patient with baseline + summary longitudinal outcomes (decline rates, 5-year mortality flags); there is no per-visit longitudinal panel in this SKU.
Subtype-conditioned distributions; some fields are marginal draws. Demographics, HRCT, PFT, biomarkers, and genetics are conditioned on ILD subtype (correct modeling), but several outcome and comorbidity flags are drawn at fixed prevalences rather than fully jointly conditioned on each patient's complete feature vector.
Mortality and AE outcomes are calibrated Bernoulli/probability fields. 5-year mortality and AE 90-day mortality are probability/flag draws calibrated to registry rates rather than an integrated time-to-event survival process (overall survival months are provided separately as a Weibull draw).
Disease-specific fields are blank when not applicable. Fields like trial-drug name or AE-specific values are "N/A"/NaN outside the relevant subgroup — this is correct conditional structure, not missing data.

General caveat: cross-field correlations beyond those explicitly modeled may be weaker than in real cohorts. Not for clinical decision-making — research/development use only.

Commercial product comparison

Capability	This sample	Full HC-RES-007 product
Patients	500	15,000+ (configurable)
Seeds / cohorts	1	Multi-seed, reproducible
Subtype filtering	Full mix	IPF / HP / CTD-ILD / NSIP / COP / SR-ILD
Formats	CSV	CSV + Parquet + JSON + FHIR
Longitudinal data	Summary rates	Optional per-visit panel
Outcomes	Calibrated probabilities	Integrated survival model
License	CC-BY-NC-4.0	Commercial
Support & SLA	—	Included

Full product, custom cohorts, or other respiratory SKUs (asthma, COPD, pneumonia, TB, COVID-19, lung function monitoring): pradeep@xpertsystems.ai

Citation

@dataset{xpertsystems_hc_res_007_2026,
  title        = {HC-RES-007: Pulmonary Fibrosis (ILD) Synthetic Dataset},
  author       = {XpertSystems.ai},
  year         = {2026},
  publisher    = {XpertSystems.ai Synthetic Data Factory},
  url          = {https://xpertsystems.ai},
  note         = {Synthetic; CC-BY-NC-4.0 (sample). Calibrated to: CAPACITY and ASCEND
                  (pirfenidone); INPULSIS-1/2 and TOMORROW (nintedanib, FVC decline);
                  IPF-PRO Registry (epidemiology, adherence); ILD-GAP model (staging);
                  ATS/ERS 2022 ILD guidelines; Fleischner Society 2018 (HRCT patterns).
                  Covers IPF/HP/CTD-ILD/NSIP/COP/SR-ILD with HRCT, PFT, antifibrotics,
                  biomarkers, MUC5B genetics, acute exacerbation, and transplant. Seventh SKU
                  in the XpertSystems Respiratory vertical; passes 28/28 internal benchmarks.}
}

Synthetic data generated by XpertSystems.ai. Not derived from real patient records. Not for clinical use.

Downloads last month: 27